NEW YORK, Oct. 31 - Genetix Group of New Milton, UK, said Wednesday it had agreed to collaborate with Sense Proteomic to develop a new line of protein arrays.

Genetix said it agreed to work with Sense Proteomic’s of Cambridge, UK, to deploy Sense’s COVET technology in four prototype products. The companies expect to launch the new arrays commercially next year. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.